APSR2026-313

 
Late-Breaking
Submitted
Poster Presentation
 
AP02-011
P19
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1216255-46904-APSR-313_439625.pdf
Format: PDF Only
05. Respiratory Infections (non-tuberculous)
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Albert Yick-Hou Lim - Tan Tock Seng Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore Nanyang Technological University Lee Kong Chian School of Medicine Singapore Singapore National University of Singapore Yong Loo Lin School of Medicine Singapore Singapore
Teng Ann Lee * Tan Tock Seng Hospital Department of General Medicine Singapore Singapore
Kok Kong Chong - Tan Tock Seng Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Johnny Che-I Su - Tan Tock Seng Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Miyen Chua - Tan Tock Seng Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Julian Chan - Tan Tock Seng Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Xiaona Wang - Tan Tock Seng Hospital Department of Nursing Singapore Singapore
 
 
 
 
 
 
 
 
Presenting Author Details
Teng Ann
Lee
lee.teng.ann@nhghealth.com.sg
+6586307809
31-40
Singapore
Original Research
An evaluation of the safety and feasibility of home-based antibiotic nebulization for patients with bronchiectasis.
Maximum 25 words
Abstract Content
Nebulised antibiotics are recommended for treatment of bronchiectasis patients with chronic Pseudomonas aeruginosa (P. aeruginosa) infection and Mycobacterium abscessus (M. abscessus) pulmonary disease. While inhaled antibiotics are effective, data on the safety and feasibility of home-based nebulization remain limited. This study evaluates the safety and feasibility of home-based antibiotic nebulization.
All bronchiectasis patients receiving home nebulised antibiotics between 2015 and 2025 were included. Indications were: (1) P. aeruginosa isolated twice within three months despite appropriate treatment, (2) M. abscessus pulmonary disease meeting ATS criteria, (3) good adherence to prior therapy, and (4) strong family support. Pregnancy, inability to follow instructions, and haemoptysis were excluded. The nebulisation challenge was supervised at the clinic. Training on preparation, administration and competency assessment was provided by respiratory physician and specialist nurse. Patients and carers had telephone access to the bronchiectasis team. Demographics, sputum microbiology, comorbidities, and adverse events were analysed.
A total of 33 patients (26 female) received nebulised gentamicin and 29 patients (19 female) received nebulised amikacin. Median age was higher in the gentamicin group (69 vs. 60, p=0.008), as was body mass index (BMI) (21 vs. 17, p=0.002). Smoking status, breathlessness, cough, and sputum score (BCSS) were similar between groups. The median FEV1 (%) predicted was similar across groups (gentamicin: 47, amikacin: 56, p=0.5). The amikacin group had a lower bronchiectasis severity index (BSI) (7 vs. 9, p=0.009). During the first dose challenge, adverse events included wheeze (11% gentamicin, 7% amikacin), cough (7% amikacin), chest tightness (7% amikacin), and throat tightness (3% amikacin). During treatment, sore throat was most common, followed by haemoptysis and dry mouth.
Home-based nebulised antibiotic therapy is safe and feasible in carefully selected, clinically stable patients with adequate education, monitoring, and access to specialist care.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Bronchiectasis, Antibiotics, Nebulization
maximum 3 keywords and no abbreviations, separated by commas
 
294